{"id":"salbutamol-hfa-152a","safety":{"commonSideEffects":[{"rate":"null","effect":"Tremor"},{"rate":"null","effect":"Nervousness"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL5968455","moleculeType":null,"molecularWeight":"418.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by binding to beta-2 adrenergic receptors in the bronchial smooth muscle, causing bronchodilation and reducing airway resistance. This results in improved lung function and relief of symptoms in patients with asthma and COPD.","oneSentence":"Salbutamol HFA-152a is a short-acting beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:20.054Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance and relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06261957","phase":"PHASE3","title":"A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-31","conditions":"Asthma","enrollment":477},{"nctId":"NCT06433908","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-06-04","conditions":"Asthma, Healthy Participants","enrollment":60},{"nctId":"NCT06433921","phase":"PHASE1","title":"A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-08-14","conditions":"Asthma, Mild Asthma","enrollment":84},{"nctId":"NCT05791565","phase":"PHASE1","title":"Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-04-03","conditions":"Asthma","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Salbutamol HFA-152a","genericName":"Salbutamol HFA-152a","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Salbutamol HFA-152a is a short-acting beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs. Used for Maintenance and relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}